Le Lézard
Classified in: Health
Subjects: SVY, LGB

New Study from The Fenway Institute Finds Significant Barriers to Gender-Affirming Primary Care among Transgender People Living in Rural Areas


Two-thirds of study participants reported that there were no gender-affirming clinicians available where they access primary care

BOSTON, Aug. 18, 2022 /PRNewswire-PRWeb/ -- A study published in LGBT Health found a high prevalence of barriers to gender-affirming primary care among transgender and gender diverse (TGD) people living in rural areas across five Northeastern states. Findings from the study also suggest that TGD people in rural areas receive suboptimal levels of preventive sexual health screening. The study contributes important new knowledge to the primary care needs of rural-dwelling TGD people, as nearly all of the existing literature on the primary care needs of TGD people focuses on those who live in urban areas.

"One quarter of participants in this study reported that they had no access at all to gender-affirming primary care and nearly 10 percent reported that they had been refused care by a doctor," said study senior author Dr. Alex S. Keuroghlian, who directs the National LGBTQIA+ Health Education Center at The Fenway Institute and the Massachusetts General Hospital Psychiatry Gender Identity Program. "These findings point to a real need for more comprehensive training in gender-affirming health care for all primary care clinicians."

The study, titled "Gender-Affirming Primary Care Access Among Rural Transgender and Gender Diverse Adults in Five Northeastern U.S. States," surveyed 244 TGD adults residing in rural counties of less than 500 people per square mile in Connecticut, Massachusetts, New Hampshire, New York, and Vermont. Participants were asked questions about where they received primary care and if they experienced any barriers to care. Approximately 40 percent of participants identified as nonbinary or gender diverse, 33.5 percent identified as transgender men, and 26.2 identified as transgender women.

Important findings from this study include the following:

Additionally, 59 percent of study participants reported a lack of overall clinical skill among clinicians. High percentages of participants reported that they had never been tested for HIV (20.3%) or any sexually-transmitted infections (18%) which suggests suboptimal levels of preventive sexual health screening regardless of access to gender-affirming primary care.

"This study suggests that there are plenty of opportunities to make system-level improvements in primary care for transgender and gender diverse adults living in rural areas," Keuroghlian added. "Interventions are needed to alleviate the higher burden of adverse health outcomes experienced by transgender people."

"Gender-Affirming Primary Care Access Among Rural Transgender and Gender Diverse Adults in Five Northeastern U.S. States" is available here.

Media Contact

Christopher Viveiros, Fenway Health, 6179276342, [email protected]

 

SOURCE Fenway Health


These press releases may also interest you

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...



News published on and distributed by: